{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:25:48Z","timestamp":1792301148454,"version":"4.4.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>This study aimed to use central and peripheral assays to compare the effects of the muscarinic antagonist scopolamine with those of a novel muscarinic antagonist, L-687,306 [(3R,4R)-3-(3-cyclopropyl-1,2,4,oxadiazol[5-yl]-1-azabicyclo[2.2.1]heptane. Groups of rats were trained to discriminate the stimulus effects of the muscarinic agonist, arecoline (1.0\u2009mg\/kg); concomitant measures of response rate were recorded. Separate groups were prepared with telemetery devices for recording bradycardia induced by arecoline (10\u2009mg\/kg). Methyl arecoline and arecoline were nearly equally potent in producing a brief but profound bradycardia, indicative of an equivalent effect in the heart. L-687,306 and scopolamine were both able to block this peripheral effect of arecoline. L-687,306 produced a surmountable antagonism of both the discriminative and rate-suppressing effects of arecoline. Scopolamine, however, was unable to antagonize the rate-reducing effects of arecoline in the discrimination assay. This limited the number of rats that could respond to the discriminative stimulus effects of arecoline, as well as the amount of arecoline stimulus effects they were able to report. The data suggest that L-687,306 may be a more generally effective muscarinic antagonist than scopolamine and support earlier reports that this antagonist has less direct effect on behavior.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000537","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T16:59:42Z","timestamp":1578675582000},"page":"359-367","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of the muscarinic antagonist effects of scopolamine and L-687,306"],"prefix":"10.1097","volume":"31","author":[{"given":"Gail","family":"Winger","sequence":"first","affiliation":[{"name":"Department of Pharmacology, University of Texas Health, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Jutkiewicz","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Woods","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Texas Health, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230910","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction.","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"R2-20230910","first-page":"591","article-title":"Differentiation between mu and kappa receptor-mediated effects in opioid drug discrimination: apparent pa2 analysis.","volume":"243","author":"Bertalmio","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"R3-20230910","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fneur.2016.00167","article-title":"Why an M1 antagonist could be a more selective model for memory impairment than scopolamine.","volume":"7","author":"Blokland","year":"2016","journal-title":"Front Neurol"},{"key":"R4-20230910","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.3037705","article-title":"Identification of a family of muscarinic acetylcholine receptor genes.","volume":"237","author":"Bonner","year":"1987","journal-title":"Science"},{"key":"R5-20230910","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study.","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Internal Med"},{"key":"R6-20230910","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0163-7258(93)90027-B","article-title":"Muscarinic receptors\u2013characterization, coupling and function.","volume":"58","author":"Caulfield","year":"1993","journal-title":"Pharmacol Ther"},{"key":"R7-20230910","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0166-4328(93)90130-I","article-title":"The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory.","volume":"57","author":"Dawson","year":"1993","journal-title":"Behav Brain Res"},{"key":"R8-20230910","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.vascn.2009.07.003","article-title":"Repeated assessment of cardiovascular and respiratory functions using combined telemetry and whole-body plethysmography in the rat.","volume":"60","author":"Delaunois","year":"2009","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R9-20230910","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1212\/WNL.27.8.783","article-title":"Memory and cognitive function in man: does the cholinergic system have a specific role?","volume":"27","author":"Drachman","year":"1977","journal-title":"Neurology"},{"key":"R10-20230910","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41380-018-0219-x","article-title":"Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics.","volume":"24","author":"Dulawa","year":"2019","journal-title":"Mol Psychiatry"},{"key":"R11-20230910","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1365-2362.1998.00393.x","article-title":"Scopolamine model of dementia: electroencephalogram findings and cognitive performance.","volume":"28","author":"Ebert","year":"1998","journal-title":"Eur J Clin Invest"},{"key":"R12-20230910","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s disease: targeting the cholinergic system.","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"R13-20230910","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0014-2999(92)90618-E","article-title":"L-687,306: a functionally selective and potent muscarinic M1 receptor agonist.","volume":"215","author":"Freedman","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"R14-20230910","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0024-3205(93)90306-N","article-title":"The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo.","volume":"52","author":"Freedman","year":"1993","journal-title":"Life Sci"},{"key":"R15-20230910","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4088\/JCP.13ac08584","article-title":"Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects.","volume":"74","author":"Furey","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"R16-20230910","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0091-3057(90)90051-I","article-title":"Relationship of the behavioral effects of aprophen, atropine and scopolamine to antagonism of the behavioral effects of physostigmine.","volume":"37","author":"Genovese","year":"1990","journal-title":"Pharmacol Biochem Behav"},{"key":"R17-20230910","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0091-3057(95)02018-7","article-title":"Differential effects of anticholinergic drugs on paired discrimination performance.","volume":"53","author":"Grauer","year":"1996","journal-title":"Pharmacol Biochem Behav"},{"key":"R19-20230910","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00179923","article-title":"Discriminative stimulus properties of muscarinic agonists.","volume":"93","author":"Jung","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"R20-20230910","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.drugalcdep.2012.12.021","article-title":"Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats.","volume":"131","author":"Jutkiewicz","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R21-20230910","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1124\/jpet.111.182170","article-title":"Patterns of nicotinic receptor antagonism: nicotine discrimination studies.","volume":"339","author":"Jutkiewicz","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R22-20230910","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1567205013666160930112625","article-title":"Beyond acetylcholinesterase inhibitors: novel cholinergic treatments for Alzheimer\u2019s disease.","volume":"14","author":"Kamkwalala","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"R23-20230910","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.neubiorev.2010.04.001","article-title":"The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies.","volume":"34","author":"Klinkenberg","year":"2010","journal-title":"Neurosci Biobehav Rev"},{"key":"R24-20230910","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF02245315","article-title":"Central versus peripheral effects of muscarinic antagonists: the limitations of quaternary ammonium derivatives.","volume":"108","author":"Moore","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"R25-20230910","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ijnp\/pyy051","article-title":"Neurophysiological changes associated with antidepressant response to ketamine not observed in a negative trial of scopolamine in major depressive disorder.","volume":"22","author":"Park","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"R27-20230910","first-page":"796","article-title":"Comparison of in vitro actions with behavioral effects of antimuscarinic agents.","volume":"242","author":"Witkin","year":"1987","journal-title":"J Pharmacol Exp Therap"},{"key":"R28-20230910","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/BF00439454","article-title":"Central and peripheral muscarinic actions of physostigmine and oxotremorine on avoidance responding of squirrel monkeys.","volume":"97","author":"Witkin","year":"1989","journal-title":"Psycho-pharmacology (Berlin)"},{"key":"R26-20230910","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ejphar.2013.10.065","article-title":"Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: determination of the functional half life of flumazenil.","volume":"723","author":"Zanettini","year":"2014","journal-title":"Eur J Pharmacol"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:08:31Z","timestamp":1694333311000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000537","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}